Using ceramide-rich platforms to improve cancer treatment with gemcitabine
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11000305
This study is looking at how a special enzyme in blood vessel cells can help make cancer treatments like gemcitabine work better, with the goal of improving outcomes for patients with different types of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11000305 on ClinicalTrials.gov |
What this research studies
This research investigates how activating a specific enzyme called acid sphingomyelinase (ASMase) in tumor blood vessel cells can enhance the effectiveness of cancer treatments like gemcitabine. By understanding the role of ceramide-rich platforms formed by ASMase activation, the study aims to improve the response of tumors to chemotherapy and radiation. The approach involves manipulating the timing of anti-angiogenic drugs to maximize their impact on tumor cells, potentially leading to better treatment outcomes for patients with various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that are being treated with gemcitabine or other chemotherapies, particularly those with metastatic sarcoma.
Not a fit: Patients who are not undergoing treatment for cancer or those with tumors that do not respond to gemcitabine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve patient survival and quality of life.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating that manipulating ASMase activity can enhance the effectiveness of cancer therapies.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOLESNICK, RICHARD N — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: KOLESNICK, RICHARD N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.